Skip to main content
Log in

Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Clinical aspects and pathology of pulmonary hypertension (PH) in patients with systemic lupus erythematosus (SLE) have been reported to be similar to those in patients with idiopathic pulmonary arterial hypertension (IPAH). To determine whether PH in these patients is similar, we compared the clinical characteristics, hemodynamics at diagnosis, and survival in groups of patients with SLE–PH and IPAH. We reviewed the case records of 20 patients with SLE–PH and 34 patients with IPAH, who had been assessed by echocardiography or right cardiac catheterization at Asan Medical Center, Seoul, Korea, from January 1995 to October 2003. Clinical features, laboratory data, chest X-rays, electrocardiogram results, pulmonary function tests, pulmonary perfusion scans, echocardiographic findings, serologic profiles, and survival were compared in the two groups of patients. The mean follow-up period was 18.1±20.6 months for patients with SLE–PH and 33.0±23.4 months for patients with IPAH. During follow-up, 12 SLE–PH (60%) and 11 IPAH (32%) patients died. For SLE–PH, the 3-year survival rate was 44.9% and the 5-year survival rate was 16.8%. For IPAH, the 3-year survival rate was 73.4% and the 5-year survival rate was 68.2% (p=0.02). There were no other significant differences in clinical characteristics and laboratory data between the two groups. In contrast to previous reports that the prognosis of patients with pulmonary arterial hypertension associated with collagen vascular disease was better than that of patients with IPAH, we found that the prognosis of patients with SLE–PH was much worse than that of patients with IPAH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Perez HD, Kramer N (1981) Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum 11:177–181

    Article  PubMed  CAS  Google Scholar 

  2. Quismorio FP Jr, Sharma O, Koss M, Boylen T, Edmiston AW, Thornton PJ, Tatter D (1984) Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13:349–359

    Article  PubMed  Google Scholar 

  3. Winslow TM, Ossipov MA, Fazio GP, Simonson JS, Redberg RF, Schiller NB (1995) Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 129:510–515

    Article  PubMed  CAS  Google Scholar 

  4. Pan TL, Thumboo J, Boey ML (2000) Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 9:338–342

    Article  PubMed  CAS  Google Scholar 

  5. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N (2002) Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 29:282–287

    PubMed  Google Scholar 

  6. Asherson RA, Hackett D, Gharavi AE, Harris EN, Kennedy HG, Hughes GR (1986) Pulmonary hypertension in systemic lupus erythematosus: a report of three cases. J Rheumatol 13:416–420

    PubMed  CAS  Google Scholar 

  7. Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR (1990) Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 17:1292–1298

    PubMed  CAS  Google Scholar 

  8. Kim WU, Min JK, Lee SH, Park SH, Cho CS, Kim HY (1999) Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol 17:539–545

    PubMed  CAS  Google Scholar 

  9. British Cardiac Society Guidelines and Medical Practice Committee (2001) Recommendations on the management of pulmonary hypertension in clinical practice. Heart 86(Suppl 1):I1–I13

    Google Scholar 

  10. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    PubMed  CAS  Google Scholar 

  11. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK et al (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107:216–223

    PubMed  CAS  Google Scholar 

  12. Murata I, Takenaka K, Yoshinoya S, Kikuchi K, Kiuchi T, Tanigawa T, Ito K (1997) Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest 111:36–43

    PubMed  CAS  Google Scholar 

  13. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:5S–12S

    Article  PubMed  Google Scholar 

  14. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12:265–270

    Article  PubMed  CAS  Google Scholar 

  15. Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M (1998) Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 32:1068–1073

    Article  PubMed  CAS  Google Scholar 

  16. Orens JB, Martinez FJ, Lynch JP 3rd (1994) Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 20:159–193

    PubMed  CAS  Google Scholar 

  17. Simonson JS, Schiller NB, Petri M, Hellmann DB (1989) Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 16:918–925

    PubMed  CAS  Google Scholar 

  18. Li EK, Tam LS (1999) Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 26:1923–1929

    PubMed  CAS  Google Scholar 

  19. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36:239–243

    Article  PubMed  CAS  Google Scholar 

  20. Pines A, Kaplinsky N, Goldhammer E, Olchovsky D, Frankl O (1982) Corticosteroid responsive pulmonary hypertension in systemic lupus erythematosus. Clin Rheumatol 1:301–304

    Article  PubMed  CAS  Google Scholar 

  21. Morelli S, Giordano M, De Marzio P, Priori R, Sgreccia A, Valesini G (1993) Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus. Lupus 2:367–369

    PubMed  CAS  Google Scholar 

  22. Groen H, Bootsma H, Postma DS, Kallenberg CG (1993) Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol 20:1055–1057

    PubMed  CAS  Google Scholar 

  23. Sanchez O, Humbert M, Sitbon O, Simonneau G (1999) Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 54:273–277

    Article  PubMed  CAS  Google Scholar 

  24. Gonzalez-Lopez L, Cardona-Munoz EG, Celis A, Garcia-de la Torre I, Orozco-Barocio G, Salazar-Paramo M, Garcia-Gonzalez C, Garcia-Gonzalez A, Sanchez-Ortiz A, Trujillo-Hernandez B, Gamez-Nava JI (2004) Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 13:105–112

    Article  PubMed  CAS  Google Scholar 

  25. Padmakumar K, Singh RR, Rai R, Malaviya AN, Saraya AK (1990) Lupus anticoagulants in systemic lupus erythematosus: prevalence and clinical associations. Ann Rheum Dis 49:986–989

    Article  PubMed  CAS  Google Scholar 

  26. Martinuzzo ME, Pombo G, Forastiero RR, Cerrato GS, Colorio CC, Carreras LO (1998) Lupus anticoagulant, high levels of anticardiolipin, and anti-beta2-glycoprotein I antibodies are associated with chronic thromboembolic pulmonary hypertension. J Rheumatol 25:1313–1319

    PubMed  CAS  Google Scholar 

  27. Colorio CC, Martinuzzo ME, Forastiero RR, Pombo G, Adamczuk Y, Carreras LO (2001) Thrombophilic factors in chronic thromboembolic pulmonary hypertension. Blood Coagul Fibrinolysis 12:427–432

    Article  PubMed  CAS  Google Scholar 

  28. Buchanan RR, Wardlaw JR, Riglar AG, Littlejohn GO, Miller MH (1989) Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease. J Rheumatol 16:757–761

    PubMed  CAS  Google Scholar 

  29. Mayumi T, Nagasawa K, Inoguchi T, Yamauchi Y, Ishii Y, Tada Y, Umeda F, Niho Y (1991) Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant. Ann Rheum Dis 50:543–547

    PubMed  CAS  Google Scholar 

  30. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Domenech I, Aydintug AO, Jedryka-Goral A, de Ramon E et al (1993) Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European working party on systemic lupus erythematosus. Medicine (Baltimore) 72:113–124

    CAS  Google Scholar 

  31. Rich S, Kieras K, Hart K, Groves BM, Stobo JD, Brundage BH (1986) Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 8:1307–1311

    Article  PubMed  CAS  Google Scholar 

  32. Yousem SA (1990) The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 21:467–474

    Article  PubMed  CAS  Google Scholar 

  33. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D (1995) Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151:1628–1631

    PubMed  CAS  Google Scholar 

  34. Ohar J, Polatty C, Robichaud A, Fowler A, Vetrovec G, Glauser F (1985) The role of vasodilators in patients with progressive systemic sclerosis. Interstitial lung disease and pulmonary hypertension. Chest 88:263S–265S

    PubMed  CAS  Google Scholar 

  35. Chaouat A, Weitzenblum E, Higenbottam T (1996) The role of thrombosis in severe pulmonary hypertension. Eur Respir J 9:356–363

    Article  PubMed  CAS  Google Scholar 

  36. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903

    Article  PubMed  CAS  Google Scholar 

  37. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121:409–415

    PubMed  CAS  Google Scholar 

  38. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, Mandayam S, Ginzton LE, Brundage BH (1997) Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30:343–349

    Article  PubMed  CAS  Google Scholar 

  39. McLaughlin VV, Genthner DE, Panella MM, Rich S (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338:273–277

    Article  PubMed  CAS  Google Scholar 

  40. Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE (2000) Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 117:14–18

    Article  PubMed  CAS  Google Scholar 

  41. Horn EM, Barst RJ, Poon M (2000) Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 118:1229–1230

    Article  PubMed  CAS  Google Scholar 

  42. Gomez-Sanchez MA, de la Calzada CS, Gomez Pajuelo C, Tascon JC, Alonso M, Andreu J, Aranzana M, de la Fuente A (1991) Different hemodynamic responses between acute and chronic infusion of iloprost (prostacyclin-stable analogue) in severe pulmonary hypertension. Am Rev Respir Dis 144:1404–1405

    PubMed  CAS  Google Scholar 

  43. Mok MY, Tse HF, Lau CS (1999) Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. Lupus 8:328–331

    Article  PubMed  CAS  Google Scholar 

  44. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H (2000) Long–term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342:1866–1870

    Article  PubMed  CAS  Google Scholar 

  45. Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N (1996) Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 78:244–247

    Article  PubMed  CAS  Google Scholar 

  46. Ooiwa H, Miyazawa T, Yamanishi Y, Hiyama K, Ishioka S, Yamakido M (2000) Successful treatment of systemic lupus erythematosus and pulmonary hypertension with intravenous prostaglandin I2 followed by its oral analogue. Intern Med 39:320–323

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bin Yoo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chung, SM., Lee, CK., Lee, E.Y. et al. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 25, 866–872 (2006). https://doi.org/10.1007/s10067-006-0206-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0206-5

Keywords

Navigation